| Followers | 122 |
| Posts | 12252 |
| Boards Moderated | 0 |
| Alias Born | 11/08/2021 |
Tuesday, October 25, 2022 2:24:53 PM
I would proffer that the lack of information has led to investors making decisions on faith rather than fact, and has scared away institutional investors for that reason. Any small shred of “evidence” that favors buying NWBO could easily be followed by an entire basket of negative information that could bring down the house. We just don’t know and have very little information to weigh the risks and rewards. Owning this stock is now pure speculation.
Bullshit.
Fist, most institutions are limited into what they can purchase and sub $1 OTC stocks are usually not on the allowable list.
An entire basket of negative information? LOL. Yes, there is a lot of utter nonsense out there.
Pure speculation? More bullshit. Read the last few PRs. We know that the PIP is complete, which is usually one of the last steps on the MAA/BLA process. We know that the MHRA explicitly approved the ECA trial design. We know that the FDA implicitly improved the trial design. We know that commercial manufacturing certification is expected by years end. We know the TLD, and the data is great.
The only 'speculation' I see is the bullshit narratives being spread around.
Have a great one poorman!
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
